^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    SDC2 (Syndecan 2)

    i
    Other names: SDC2, Syndecan 2, Fibroglycan 2, SYND2, Heparan Sulfate Proteoglycan 1 Cell Surface-Associated, Heparan Sulfate Proteoglycan Core Protein, Syndecan Proteoglycan 2, Syndecan-2, CD362, HSPG1, HSPG, Cell Surface-Associated Heparan Sulfate Proteoglycan 1, CD362 Antigen
    Associations

    News

    Trials
    8d
    Fecal DNA SDC2 methylation test for colorectal cancer diagnosis: A systematic review and meta-analysis. (PubMed, Biomol Biomed)
    Deeks' funnel plot asymmetry tests indicated no statistically significant publication bias (p = 0.48 and 0.54). In conclusion, fecal mSDC2 testing demonstrates high diagnostic accuracy for CRC detection when compared to individuals with normal mucosa and moderate performance against benign colorectal lesions. These findings suggest that mSDC2 may serve as a promising noninvasive biomarker to complement existing CRC screening methodologies.
    Clinical • Retrospective data • Journal
    |
    SDC2 (Syndecan 2)
    12d
    Stool DNA-based SDC2 Methylation Test for the Screening of Colorectal Neoplasia in an Asymptomatic, Average-Risk Population. (PubMed, Korean J Gastroenterol)
    Among those with a positive meSDC2 test, a family history of CRC was a significant predictor of any CRN (p=0.029) and advanced neoplasia (p=0.003). A stool DNA-based meSDC2 test in average-risk individuals for CRC revealed a high PPV for any CRN in a real-world setting, highlighting its potential as a screening modality in programmatic CRC screening.
    Clinical • Retrospective data • Journal
    |
    SDC2 (Syndecan 2)
    25d
    Stool- and Blood-Associated Colorectal Cancer Biomarkers: A Systematic Review. (PubMed, Cancers (Basel))
    DNA methylation and microRNA biomarkers hold strong promises for non-invasive CRC screening. Multi-marker panels demonstrate superior diagnostic accuracy and may provide a cost-effective, scalable approach for early CRC detection in resource-limited settings.
    Review • Journal
    |
    MIR21 (MicroRNA 21) • MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9) • BCAT1 (Branched Chain Amino Acid Transaminase 1 ) • MIR182 (MicroRNA 182) • MIR223 (MicroRNA 223) • SYNE1 (Spectrin Repeat Containing Nuclear Envelope Protein 1) • WIF1 (WNT Inhibitory Factor 1) • SDC2 (Syndecan 2) • SEPTIN9 (Septin 9) • SHOX2 (SHOX Homeobox 2)
    2ms
    Stool-based methylated syndecan-2 test and fecal immunochemical test for advanced colorectal neoplasia screening in the Chinese population: A multicenter randomized noncomparative study. (PubMed, Chin Med J (Engl))
    This study revealed the effectiveness of the mSDC2 test and FIT in detecting advanced colorectal neoplasia in a large Chinese population in a real-world setting, and indicated a possible improvement in adherence to colonoscopy for the mSDC2 test. Further studies with improved comparability and longer follow-up are warranted to clarify its clinical utility.
    Journal
    |
    SDC2 (Syndecan 2)
    2ms
    Insect-Spinach Waste Synergy: Enhancing Cyamopsis tetragonoloba under Copper Stress. (PubMed, ACS Omega)
    Image analysis confirmed that callus morphology and growth were preserved, compared with the control. These results highlight the safe use of FHSPF2 and FHSPG1 NPs in agricultural biotechnology and biomedical applications, providing a sustainable approach to mitigate heavy metal stress and enhance plant resilience.
    Journal
    |
    SDC2 (Syndecan 2)
    3ms
    Evaluating the cross-reactivity of a stool methylated syndecan-2 (meSDC2) test in colorectal cancer detection. (PubMed, J Gastrointest Oncol)
    The stool meSDC2 test demonstrated a high positivity rate in CRC but showed low positivity rates in other cancers, except in biliary tract cancer. This indicates that the stool meSDC2 test has a high specificity for CRC, as the results are minimally influenced by other cancer types.
    Journal
    |
    SDC2 (Syndecan 2)
    3ms
    Targeting syndecan-2 inhibits papillary thyroid cancer invasiveness and de-differentiation. (PubMed, BMC Endocr Disord)
    Our findings suggest that SDC2 would be a promising therapy target for advanced radioiodine refractory thyroid cancer, but the role in PTC progression is complicated and requires further exploration.
    Journal
    |
    TJP1 (Tight Junction Protein 1) • SDC2 (Syndecan 2)
    4ms
    An Automated Multi-Sample Digital LAMP Platform for Quantitative Detection of SDC2 Methylation in Colorectal Cancer. (PubMed, Anal Chem)
    The results showed elevated SDC2 methylation was detected in tumor tissues across all CRC stages. This integrated automated dLAMP platform provides a robust, multisample high-throughput tool for methylation-based diagnostics and holds strong potential for noninvasive early cancer screening and clinical biomarker applications.
    Journal
    |
    SDC2 (Syndecan 2)
    5ms
    SDC2 and FN as cargo proteins in circulating extracellular vesicles in obese breast cancer patients with lymph node metastasis. (PubMed, Sci Rep)
    Bioinformatics analyses further confirmed the association of SDC2 and FN expression with BC staging and prognosis. These findings underscore the potential of circulating MV-enriched EV-associated SDC2 and FN, along with their tumor tissue mRNA expression, as potential predictive biomarkers for LNM and chemotherapy response in chemotherapy-naïve obese BC patients.
    Journal
    |
    SDC1 (Syndecan 1) • SDC4 (Syndecan 4) • SDC2 (Syndecan 2)
    5ms
    The Role of Epigenetic Biomarkers as Diagnostic, Predictive and Prognostic Factors in Colorectal Cancer. (PubMed, Cancers (Basel))
    Selected lncRNAs, including THOR and LINC01094, have also demonstrated significant prognostic value. Despite these advances, challenges persist, including inconsistent reporting, limited external validation, and a lack of replication by independent research groups.
    Review • Journal
    |
    ERCC1 (Excision repair cross-complementation group 1) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • MIR21 (MicroRNA 21) • GAS6 (Growth arrest specific 6) • MIR211 (MicroRNA 211) • IGFBP3 (Insulin-like growth factor binding protein 3) • LINC01094 (Long Intergenic Non-Protein Coding RNA 1094) • MIR140 (MicroRNA 140) • MIR150 (MicroRNA 150) • MIR215 (MicroRNA 215) • MIR675 (MicroRNA 675) • SDC2 (Syndecan 2) • SEPTIN9 (Septin 9) • SNHG14 (Small Nucleolar RNA Host Gene 14) • ASB16-AS1 (ASB16 Antisense RNA 1)
    5ms
    Syndecan-2 positively regulates Wnt/β-catenin signaling in breast cancer cells. (PubMed, Int J Biochem Cell Biol)
    Collectively, our results demonstrate that syndecan-2 is a positive regulator of canonical Wnt signaling. These results also suggest that syndecan-2 is a potential clinical target for inhibiting the progression of some human cancers.
    Journal
    |
    SDC2 (Syndecan 2)
    6ms
    Stool-based methylated syndecan-2 testing has a high positive predictive value in an average/increased-risk population: a multicenter retrospective study. (PubMed, Gastroenterol Rep (Oxf))
    The mSDC2 test, which has a high PPV for both ACN and CRC, is expected to be an alternative CRC screening strategy. Patients with a positive mSDC2 test might require a colonoscopy as soon as possible, even if the previous colonoscopy was negative.
    Retrospective data • Journal
    |
    SDC2 (Syndecan 2)